Theranostic Heterodimeric Prodrug with Dual‐Channel Fluorescence Turn‐On and Dual‐Prodrug Activation for Synergistic Cancer Therapy
Abstract
Theranostic prodrugs that can precisely monitor drug activation with synergistic therapeutic effects are highly desirable for personalized medicine. In this study, a theranostic heterodimeric prodrug, CyNH-SS-DOX, with synchronous and independent dual-channel fluorescence turn-on and dual-prodrug activation for synergistic cancer therapy is developed. A hemicyanine fluorescent drug, CyNH2 , with good therapeutic effects found in this work, is...
Paper Details
Title
Theranostic Heterodimeric Prodrug with Dual‐Channel Fluorescence Turn‐On and Dual‐Prodrug Activation for Synergistic Cancer Therapy
Published Date
Aug 28, 2021
Volume
10
Issue
21
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History